# Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.

> **NCT04343144** · PHASE2 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 92 (estimated)

## Conditions studied

- COVID19- Infection With SARS-CoV-2 Virus

## Interventions

- **DRUG:** Nivolumab Injection

## Key facts

- **NCT ID:** NCT04343144
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-15
- **Primary completion:** 2020-07-31
- **Final completion:** 2020-09-30
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2020-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04343144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04343144, "Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT04343144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*